Company: CMND
Filing Date: 2025-09-19
Form Type: F-1
Source: 0001213900-25-089545
Chunk: 11

Company: Clearmind Medicine Inc.
Filing Date: 2025-09-19
Form: F-1
Chunk 11
---
 Gan, Israel) to advance the evaluation of MEAI as a potential treatment for addictions and other binge behaviors. Prof. Yadid,
a prominent figure in the research and development of treatments for psychiatric disease, specifically drug addiction, depression, and
PTSD, and his team conducted a series of studies to explore the mechanism of action and specific neural targets of MEAI to evaluate its
efficacy as a potential therapeutic agent in the treatment of addiction and related behaviors. The results of pre-clinical research studies
suggested that MEAI may be effective in the treatment of substance addiction and specifically cocaine without interrupting the natural
reward process. According to the United Nations Office on Drugs and Crime’s “2022 World Drug Report”, of the estimated
284 million people who had used drugs in the past year, approximately 13.6%, 38.6 million, are estimated to have suffered from drug use
disorders. While some addictions, such as drugs and alcohol, are more concerning than others, addiction and compulsive behavior is not
limited to these substances. Compulsive consumption of food, shopping, gambling, sex, television, and technology, many of which increased
in prevalence during the recent pandemic, can all be destructive when their use cannot be managed and all can potentially be treated by
MEAI.

Corporate Information

We were incorporated under
the name Cyntar Ventures Inc. on July 18, 2017, pursuant to the provisions of the Business Corporations Act(British
Columbia). On March 24, 2021, we changed our name to Clearmind Medicine Inc.

Our principal executive offices
are located at 101 – 1220 W. 6th Ave, Vancouver, BC V6H1A5. Our telephone number is 973.536.1016. Our website address is https://www.clearmindmedicine.com/.
The information contained on our website and available through our website is not incorporated by reference into and should not be considered
a part of this prospectus, and the reference to our website in this prospectus is an inactive textual reference only.

Recent Developments

Convertible Notes Securities Purchase Agreement

On September 17, 2025, we
entered into the SPAs with the CLA Investors. The SPAs provide that, upon the terms and subject to the conditions set forth therein, we
shall issue and sell to the CLA Investors, as provided therein, Promissory Notes for the Subscription Amount, which may be convertible